Skip to main content
hero background ribbon

Our Pipeline

We are developing single-course gene editing medicines to disrupt today’s standard of care for cardiovascular disease. 

 

See Our Pipeline
Verve Scientist Verve team meeting Test tubes

Our Therapeutic Vision

Verve is taking a stepwise approach to clinical development with our single-course gene editing programs.

Our Pipeline

ProgramIndicationsTechnologyResearchInd-enablingClinicalRights
PCSK9
(VERVE-101)
Indications
Heterozygous familial hypercholesterolemia (HeFH)
ASCVD
Technology
Base Editor
Development Status
Clinical
Verve logoBeam logo
PCSK9
(VERVE-102)
Indications
Heterozygous familial hypercholesterolemia (HeFH)
ASCVD
Technology
Base Editor
Development Status
IND-Enabling
Verve logoBeam logo
ANGPTL3
(VERVE-201)
Indications
Homozygous familial hypercholesterolemia (HoFH)
Refractory hypercholesterolemia
Technology
Base Editor
Development Status
IND-Enabling
Verve logoBeam logo
LPA
Indications
ASCVD with High Lp(a)
Technology
Novel Editor
Development Status
Research
Verve logoLilly logo
Undisclosed
Indications
Undisclosed ASCVD
Technology
Base Editor
Development Status
Research
Verve logoBeam logo
Undisclosed
Indications
Undisclosed liver disease
Technology
Novel Editor
Development Status
Research
Verve logoVertex logo